Genprex Inc

GNPX NASDAQ
1.410
+0.030
+2.17%
After Hours: 1.410 0 0.00% 16:00 06/20 EDT
Open
1.324
Prev Close
1.380
High
1.441
Low
1.320
Volume
11.22K
Avg Vol (3M)
25.98K
52 Week High
10.28
52 Week Low
0.9500
% Turnover
0.07%
Market Cap
21.91M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Genprex Inc GNPX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Genprex, Inc. is a clinical stage gene therapy company. The Company is focused on developing cancer-based upon its novel proprietary technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. The Company’s Oncoprex is lead product candidate, is the subject of an ongoing Phase I/II clinical trials at The University of Texas MD Anderson Cancer Center in patients with late stage non-small cell lung cancer, or NSCLC. Oncoprex gene therapy platform may also be effective with respect to other types of cancer, including breast, head and neck, renal cell (kidney), soft tissue cancer. The Company’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The Company’s Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis.
MORE >

Recently

Name
Price
%Change